With regard to systemic chemotherapy, validated biomarkers such as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), and microsatellite instability (MSI) cover the extensive heterogeneity of CRC and are suitable for guiding personalized treatment. This evidence concerns the gene BRAF and colorectal carcinoma.